• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Burning Rock Biotech Limited (Amendment)

    2/13/23 10:35:06 AM ET
    $BNR
    Medical Specialities
    Health Care
    Get the next $BNR alert in real time by email
    SC 13G/A 1 tm235872d1_sc13ga.htm SC 13G/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Schedule 13G
    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b)

    (Amendment No. 1)*

     

    Burning Rock Biotech Limited

    (Name of Issuer)

     

    American Depositary Shares (ADS), each representing

    1 Class A Ordinary Share, par value $0.0002 per Share

    (Title of Class of Securities)

     

    G17173 108

    (CUSIP Number)

     

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)

     

    ¨Rule 13d-1(c)

     

    xRule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    (Continued on following pages)

     

    Page 1 of 16 Pages

    Exhibit Index Contained on Page 14

     

     

     

     

     

    CUSIP NO. G17173 108 13 G Page 2 of 16

     

    1 NAME OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    Northern Light Venture Fund III, L.P. (“NLVF III”)
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a)      ¨      
    (b)     x
          

    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Cayman Islands

     

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

    5

    SOLE VOTING POWER.

     

    10,542,529 American Depositary Shares (“shares”), except that Northern Light Partners III, L.P. (the “DGP”), the general partner of NLVF III, and Northern Light Venture Capital III, Ltd. (the “UGP”), the general partner of the DGP, may be deemed to have sole power to vote these shares, and Feng Deng (“Deng”), Yan Ke (“Ke”) and Jeffrey D. Lee (“Lee”), the directors of the UGP, may be deemed to have shared power to vote these shares.

    6

    SHARED VOTING POWER

     

    See response to row 5.

    7

    SOLE DISPOSITIVE POWER

     

    10,542,529 shares, except that the DGP, the general partner of NLVF III, and the UGP, the general partner of the DGP, may be deemed to have sole power to dispose of these shares, and Deng, Ke and Lee, the directors of the UGP, may be deemed to have shared power to dispose of these shares.

    8

    SHARED DISPOSITIVE POWER

     

    See response to row 7.

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
    REPORTING PERSON
    10,542,529
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
    EXCLUDES CERTAIN SHARES* 
    ¨      
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)     12.0%
    12 TYPE OF REPORTING PERSON* PN

     

     

     

     

    CUSIP NO. G17173 108 13 G Page 3 of 16

     

    1

    NAME OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

    Northern Light Strategic Fund III, L.P. (“NLSF III”)

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP *

    (a)      ¨      
    (b)     x
          

    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Cayman Islands

     

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

    5

    SOLE VOTING POWER

     

    1,188,025 shares, except that the DGP, the general partner of NLSF III, and the UGP, the general partner of the DGP, may be deemed to have sole power to vote these shares, and Deng, Ke and Lee, the directors of the UGP, may be deemed to have shared power to vote these shares.

    6

    SHARED VOTING POWER

     

    See response to row 5.

    7

    SOLE DISPOSITIVE POWER.

     

    1,188,025 shares, except that the DGP, the general partner of NLSF III, and the UGP, the general partner of the DGP, may be deemed to have sole power to dispose of these shares, and Deng, Ke and Lee, the directors of the UGP, may be deemed to have shared power to dispose of these shares.

    8

    SHARED DISPOSITIVE POWER

     

    See response to row 7.

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
    REPORTING PERSON
    1,188,025
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
    EXCLUDES CERTAIN SHARES* 
    ¨      
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)     1.3%
    12 TYPE OF REPORTING PERSON* PN

     

     

     

     

    CUSIP NO. G17173 108 13 G Page 4 of 16

     

    1

    NAME OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

    Northern Light Partners Fund III, L.P. (“NLPF III”)

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a)      ¨      
    (b)     x
          

    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Cayman Islands

     

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

    5

    SOLE VOTING POWER

     

    149,691 shares, except that the DGP, the general partner of NLPF III, and the UGP, the general partner of the DGP, may be deemed to have sole power to vote these shares, and Deng, Ke and Lee, the directors of the UGP, may be deemed to have shared power to vote these shares.

    6

    SHARED VOTING POWER

     

    See response to row 5.

    7

    SOLE DISPOSITIVE POWER.

     

    149,691 shares, except that the DGP, the general partner of NLPF III, and the UGP, the general partner of the DGP, may be deemed to have sole power to dispose of these shares, and Deng, Ke and Lee, the directors of the UGP, may be deemed to have shared power to dispose of these shares.

    8

    SHARED DISPOSITIVE POWER

     

    See response to row 7.

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
    REPORTING PERSON
    149,691
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
    EXCLUDES CERTAIN SHARES* 
    ¨      
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)     0.1%
    12 TYPE OF REPORTING PERSON* PN

     

     

     

     

    CUSIP NO. G17173 108 13 G Page 5 of 16

     

    1 NAME OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    Northern Light Partners III, L.P. (the “DGP”)
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a)      ¨      
    (b)     x
          

    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Cayman Islands

     

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

    5

    SOLE VOTING POWER.

     

    11,880,245 shares, of which 10,542,529 shares are beneficially owned by NLVF III, 1,188,025 shares are beneficially owned by NLSF III, and 149,691 shares are beneficially owned by NLPF III. The DGP, the general partner of NLVF III, NLSF III and NLPF III, may be deemed to have sole power to vote these shares, except that the UGP, the general partner of the DGP, may be deemed to have sole power to vote these shares, and Deng, Ke and Lee, the directors of the UGP, may be deemed to have shared power to vote these shares.

    6

    SHARED VOTING POWER

     

    See response to row 5.

    7

    SOLE DISPOSITIVE POWER

     

    11,880,245 shares, of which 10,542,529 shares are beneficially owned by NLVF III, 1,188,025 shares are beneficially owned by NLSF III, and 149,691 shares are beneficially owned by NLPF III. The DGP, the general partner of each of NLVF III, NLSF III and NLPF III, may be deemed to have sole power to dispose of these shares, except that the UGP, the general partner of the DGP, may be deemed to have sole power to dispose of these shares, and Deng, Ke and Lee, the directors of the UGP, may be deemed to have shared power to dispose of these shares.

    8

    SHARED DISPOSITIVE POWER

     

    See response to row 7.

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
    REPORTING PERSON
    11,880,245
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
    EXCLUDES CERTAIN SHARES* 
    ¨      
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)     13.5%
    12 TYPE OF REPORTING PERSON* PN

     

     

     

     

    CUSIP NO. G17173 108 13 G Page 6 of 16

     

    1 NAME OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    Northern Light Venture Capital III, Ltd. (the “UGP”)
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a)      ¨      
    (b)     x
          

    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Cayman Islands

     

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

    5

    SOLE VOTING POWER.

     

    11,880,245 shares, of which 10,542,529 shares are beneficially owned by NLVF III, 1,188,025 shares are beneficially owned by NLSF III, and 149,691 shares are beneficially owned by NLPF III. The UGP is the general partner of the DGP, the general partner of each of NLVF III, NLSF III and NLPF III, and may be deemed to have sole power to vote these shares, except the DGP, the general partner of each of NLVF III, NLSF III and NLPF III, may be deemed to have sole power to vote these shares, and Deng, Ke and Lee, the directors of the UGP, may be deemed to have shared power to vote these shares.

    6

    SHARED VOTING POWER

     

    See response to row 5.

    7

    SOLE DISPOSITIVE POWER

     

    11,880,245 shares, of which 10,542,529 shares are beneficially owned by NLVF III, 1,188,025 shares are beneficially owned by NLSF I, and 149,691 shares are beneficially owned by NLPF III. The UGP is the general partner of the DGP, the general partner of each of NLVF III, NLSF III and NLPF III, and may be deemed to have sole power to dispose of such shares, except the DGP, the general partner of each of NLVF III, NLSF III and NLPF III, may be deemed to have sole power to dispose of these shares, and Deng, Ke and Lee, the directors of the UGP, may be deemed to have shared power to dispose of these shares.

    8

    SHARED DISPOSITIVE POWER

     

    See response to row 7.

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
    REPORTING PERSON
    11,880,245
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
    EXCLUDES CERTAIN SHARES* 
    ¨      
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)     13.5%
    12 TYPE OF REPORTING PERSON* OO

      

     

     

     

    CUSIP NO. G17173 108 13 G Page 7 of 16

     

    1 NAME OF REPORTING PERSONS

    Feng Deng (“Deng”)
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a)      ¨      
    (b)     x
          

    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    U.S. Citizen

     

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

    5

    SOLE VOTING POWER.

     

    0 shares.

    6

    SHARED VOTING POWER

     

    11,880,245 shares, of which 10,542,529 shares are beneficially owned by NLVF III, 1,188,025 shares are beneficially owned by NLSF III, and 149,691 shares are beneficially owned by NLPF III. Deng is a director of the UGP, the general partner of the DGP, which is the general partner of each of NLVF III, NLSF III and NLPF III, and may be deemed to have shared power to vote these shares.

    7

    SOLE DISPOSITIVE POWER.

     

    0 shares.

    8

    SHARED DISPOSITIVE POWER.

     

    11,880,245 shares, of which 10,542,529 shares are beneficially owned by NLVF III, 1,188,025 shares are beneficially owned by NLSF III, and 149,691 shares are beneficially owned by NLPF III. Deng is a director of the UGP, the general partner of the DGP, which is the general partner of each of NLVF III, NLSF III and NLPF III, and may be deemed to have shared power to dispose of these shares.

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
    REPORTING PERSON
    11,880,245
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
    EXCLUDES CERTAIN SHARES* 
    ¨      
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)     13.5%
    12 TYPE OF REPORTING PERSON* IN

     

     

     

     

    CUSIP NO. G17173 108 13 G Page 8 of 16

     

    1 NAME OF REPORTING PERSONS

    Yan Ke (“Ke”)
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a)      ¨      
    (b)     x      

    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    U.S. Citizen

     

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

    5

    SOLE VOTING POWER.

     

    0 shares.

    6

    SHARED VOTING POWER

     

    11,880,245 shares, of which 10,542,529 shares are beneficially owned by NLVF III, 1,188,025 shares are beneficially owned by NLSF III, and 149,691 shares are beneficially owned by NLPF III. Ke is a director of the UGP, the general partner of the DGP, which is the general partner of each of NLVF III, NLSF III and NLPF III, and may be deemed to have shared power to vote these shares.

    7

    SOLE DISPOSITIVE POWER.

     

    0 shares.

    8

    SHARED DISPOSITIVE POWER.

     

    11,880,245 shares, of which 10,542,529 shares are beneficially owned by NLVF III, 1,188,025 shares are beneficially owned by NLSF III, and 149,691 shares are beneficially owned by NLPF III. Ke is a director of the UGP, the general partner of the DGP, which is the general partner of each of NLVF III, NLSF III and NLPF III, and may be deemed to have shared power to dispose of these shares.

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
    REPORTING PERSON
    11,880,245
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
    EXCLUDES CERTAIN SHARES* 
    ¨      
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)     13.5%
    12 TYPE OF REPORTING PERSON* IN

     

     

     

     

    CUSIP NO. G17173 108 13 G Page 9 of 16

     

    1 NAME OF REPORTING PERSONS

    Jeffrey D. Lee  (“Lee”)
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a)      ¨      
    (b)     x      

    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    U.S. Citizen

     

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH REPORTING
    PERSON
    WITH

    5

    SOLE VOTING POWER.

     

    0 shares.

    6

    SHARED VOTING POWER

     

    11,880,245 shares, of which 10,542,529 shares are beneficially owned by NLVF III, 1,188,025 shares are beneficially owned by NLSF III, and 149,691 shares are beneficially owned by NLPF III. Lee is a director of the UGP, the general partner of the DGP, which is the general partner of each of NLVF III, NLSF III and NLPF III, and may be deemed to have shared power to vote these shares.

    7

    SOLE DISPOSITIVE POWER.

     

    0 shares.

    8

    SHARED DISPOSITIVE POWER.

     

    11,880,245 shares, of which 10,542,529 shares are beneficially owned by NLVF III, 1,188,025 shares are beneficially owned by NLSF III, and 149,691 shares are beneficially owned by NLPF III. Lee is a director of the UGP, the general partner of the DGP, which is the general partner of each of NLVF III, NLSF III and NLPF III, and may be deemed to have shared power to dispose of these shares.

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
    REPORTING PERSON
    11,880,245
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
    EXCLUDES CERTAIN SHARES* 
    ¨      
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)     13.5%
    12 TYPE OF REPORTING PERSON* IN

     

     

     

     

    CUSIP NO. G17173 108 13 G Page 10 of 16

     

    This Amendment No. 1 amends and restates in its entirety the Schedule 13G previously filed by Northern Light Venture Fund III, L.P. (“NLVF III”), Northern Light Strategic Fund III, L.P. (“NLSF III”), Northern Light Partners Fund III, L.P. (“NLPF III”), Northern Light Partners III, L.P. (the “DGP”), Northern Light Venture Capital III, Ltd. (the “UGP”), Feng Deng (“Deng”), Yan Ke (“Ke”), and Jeffrey D. Lee (together with all prior and current amendments thereto, this “Schedule 13G”).

     

    ITEM 1(A).NAME OF ISSUER

    Burning Rock Biotech Limited

     

    ITEM 1(B).ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES

    No.5, Xingdao Ring Road North, International Bio Island
    Guangzhou 510005

    The People’s Republic of China

    ITEM 2(A).NAME OF PERSONS FILING

     

    This Schedule 13G is being filed by (i) Northern Light Venture Fund III, L.P., a Cayman Islands exempted limited partnership (“NLVF III”); (ii) Northern Light Strategic Fund III, L.P., a Cayman Islands exempted limited partnership (“NLSF III”); (iii) Northern Light Partners Fund III, L.P., a Cayman Islands exempted limited partnership (“NLPF III”); (iv) Northern Light Partners III, L.P., a Cayman Islands exempted limited partnership (the “DGP”); (v) Northern Light Venture Capital III, Ltd., a Cayman Islands exempted company (the “UGP”); (vi) Feng Deng (“Deng”), a citizen of the United States, (vii) Yan Ke (“Ke”), a citizen of the United States, and (viii) Jeffrey D. Lee (“Lee”), a citizen of the United States. The foregoing entities and individuals are collectively referred to as the “Reporting Persons.”

     

    NLVF III, NLSF III and NLPF III are venture capital funds. The DGP is the general partner of each of NLVF III, NLSF III and NLPF III and may be deemed to have sole power to vote and sole power to dispose of shares of the issuer owned by the UGP for the benefit of NLVF III, NLSF III and NLPF III. The UGP is the general partner of the DGP and may be deemed to have sole power to vote and sole power to dispose of shares of the issuer owned by the UGP for the benefit of NLVF III, NLSF III and NLPF III. Deng, Ke and Lee are the directors of the UGP and may be deemed to have shared power to vote and shared power to dispose of the shares owned by the UGP for the benefit of NLVF III, NLSF III and NLPF III.

     

    ITEM 2(B).ADDRESS OF PRINCIPAL OFFICE

     

    The principal business office of the Reporting Persons is:

     

    Northern Light Venture Capital

    Suite 2210 Two Pacific Place

    88 Queensway

    Admiralty, Hong Kong

     

    ITEM 2(C)CITIZENSHIP

    NLVF III, NLSF III, NLPF III and the DGP are Cayman Islands exempted limited partnerships. The UGP is a Cayman Islands exempted company. Lee, Deng and Ke are United States citizens.

     

    ITEM 2(D) AND (E).    TITLE OF CLASS OF SECURITIES AND CUSIP NUMBER

     

    American Depositary Shares

     

    CUSIP # G17173 108

     

     

     

     

    CUSIP NO. G17173 108 13 G Page 11 of 16

     

    ITEM 3.Not Applicable

     

    ITEM 4.

    OWNERSHIP

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    (a)Amount beneficially owned:

    See Row 9 of cover page for each Reporting Person.

     

    (b)Percent of Class:

    See Row 11 of cover page for each Reporting Person.

     

    (c)Number of shares as to which such person has:

     

    (i)Sole power to vote or to direct the vote:

    See Row 5 of cover page for each Reporting Person.

     

    (ii)Shared power to vote or to direct the vote:

     

    See Row 6 of cover page for each Reporting Person.

     

    (iii)Sole power to dispose or to direct the disposition of:

     

    See Row 7 of cover page for each Reporting Person.

     

    (iv)Shared power to dispose or to direct the disposition of:

    See Row 8 of cover page for each Reporting Person.

     

    ITEM 5.OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

    Not applicable.

     

    ITEM 6.OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.

     

    Under certain circumstances set forth in the limited partnership agreements of each of NLVF III, NLSF III, NLPF III and the DGP, and the memorandum and articles of association of the UGP, the general partner and limited partners or directors, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from, the sale of shares of the issuer owned by each such entity of which they are a general partner, limited partner or director.

     

    ITEM 7.IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY

    Not applicable.

     

     

     

     

    CUSIP NO. G17173 108 13 G Page 12 of 16

     

    ITEM 8.IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.

    Not applicable.

     

    ITEM 9.NOTICE OF DISSOLUTION OF GROUP.

    Not applicable.

     

    ITEM 10.CERTIFICATION.

    Not applicable.

     

     

     

     

    CUSIP NO. G17173 108 13 G Page 13 of 16

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 13, 2023

     

    Northern Light Venture Capital III, Ltd.

     

    Northern Light Partners III, L.P.

    By: Northern Light Venture Capital III, Ltd.,

    Its General Partner

     

    Northern Light Venture Fund III, L.P.

    By: Northern Light Partners III, L.P.,

    Its General Partner

     

    By: Northern Light Venture Capital III, Ltd.,

    Its General Partner

     

    Northern Light Strategic Fund III, L.P.

    By: Northern Light Partners III, L.P.,

    Its General Partner

     

    By: Northern Light Venture Capital III, Ltd.,

    Its General Partner

     

    Northern Light Partners Fund III, L.P.

    By: Northern Light Partners III, L.P.,

    Its General Partner

     

    By: Northern Light Venture Capital III, Ltd.,

    Its General Partner

     

     

    Feng Deng

     

    Yan Ke

     

     

     

    Jeffrey D. Lee

     

     

    By: /s/ Jeffrey D. Lee   By: /s/ Jeffrey D. Lee
      Jeffrey D. Lee, Attorney-In-Fact for the above-listed entities     Jeffrey D. Lee, Attorney-In-Fact for the above-listed individuals

     

     

     

     

    CUSIP NO. G17173 108 13 G Page 14 of 16

     

    EXHIBIT INDEX

     

      Found on
    Sequentially
    Exhibit Numbered Page
       
    Exhibit A:  Agreement of Joint Filing 15
       
    Exhibit B:  Power of Attorney 16

     

     

     

     

    CUSIP NO. G17173 108 13 G Page 15 of 16

     

    exhibit A

     

    Agreement of Joint Filing

     

    The Reporting Persons agree that a single Schedule 13G (or any amendment thereto) relating to the American Depositary Shares of Burning Rock Biotech Limited shall be filed on behalf of each of the Reporting Persons. Note that copies of the applicable Agreement of Joint Filing are already on file with the appropriate agencies.

     

     

     

     

    CUSIP NO. G17173 108 13 G Page 16 of 16

     

    exhibit B

     

    POWER OF ATTORNEY

     

    Jeffrey D. Lee has signed this Schedule 13G as Attorney-In-Fact. Note that copies of the applicable Power of Attorney are already on file with the appropriate agencies.

     

     

     

    Get the next $BNR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BNR

    DatePrice TargetRatingAnalyst
    10/15/2021Outperform
    Cowen
    7/14/2021$39.94Outperform
    CICC
    More analyst ratings

    $BNR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Burning Rock Reports First Quarter 2025 Financial Results

      GUANGZHOU, China, June 06, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock")), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2025. Recent Business Updates Therapy Selection and MRD Personalized Minimal Residual Disease (MRD) product, CanCatch® Custom supports advancement in oesophageal squamous cell carcinoma(OSCC)treatment, with results published in the Molecular Cancer in May 2025. The study is a two-arm, multicenter, randomized, doub

      6/6/25 3:31:54 AM ET
      $BNR
      Medical Specialities
      Health Care
    • Burning Rock Reports Unaudited Fourth Quarter and Full Year 2024 Financial Results

      GUANGZHOU, China, March 25, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock")), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported unaudited financial results for the three months and the year ended December 31, 2024. 2024 Business Overview and Recent Updates Corporate Updates Completed profitability-driven organizational optimization, execution towards profitability well underway Early Detection   THUNDER study for 6-cancer test was included in the Diagnosis and Treatment Guidelines for Primary Liver Cancer (2024 Edition) and the Expert Consensus on Dete

      3/25/25 7:45:42 AM ET
      $BNR
      Medical Specialities
      Health Care
    • Burning Rock Announces Results of 2024 Annual General Meeting

      GUANGZHOU, China, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"), the "Company" or "Burning Rock"), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that all shareholder resolutions proposed at the Company's 2024 annual general meeting held today were duly passed. Specifically, the shareholders passed the following resolutions: as an ordinary resolution, THAT the appointment of Ernst & Young Hua Ming LLP as auditor of the Company for the fiscal year ending December 31, 2024 be ratified and that the directors of the Company be authorize

      12/31/24 4:56:17 AM ET
      $BNR
      Medical Specialities
      Health Care

    $BNR
    Leadership Updates

    Live Leadership Updates

    See more
    • Burning Rock Announces Results of 2024 Annual General Meeting

      GUANGZHOU, China, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"), the "Company" or "Burning Rock"), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that all shareholder resolutions proposed at the Company's 2024 annual general meeting held today were duly passed. Specifically, the shareholders passed the following resolutions: as an ordinary resolution, THAT the appointment of Ernst & Young Hua Ming LLP as auditor of the Company for the fiscal year ending December 31, 2024 be ratified and that the directors of the Company be authorize

      12/31/24 4:56:17 AM ET
      $BNR
      Medical Specialities
      Health Care
    • Burning Rock Announces 2024 Annual General Meeting to be Held on December 31, 2024

      GUANGZHOU, China, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"), the "Company" or "Burning Rock"), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it will hold its annual general meeting ("AGM") on December 31, 2024 at 10:00 a.m. (local time) at the Company's Shanghai office at 6/F, Building 10C, Pujiang Smart Plaza, No. 2168 Chenhang Highway, Minhang District, Shanghai. The notice of the AGM and the form of proxy for the AGM are available on the Company's website, within Investors Relation section, at https://ir.brbiotech.com. The AG

      12/3/24 6:45:12 AM ET
      $BNR
      Medical Specialities
      Health Care
    • Burning Rock Announces Results of 2023 Annual General Meeting

      GUANGZHOU, China, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"))), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that all shareholder resolutions proposed at the Company's 2023 annual general meeting held today were duly passed. Specifically, the shareholders passed the following resolutions: To ratify the appointment of Ernst & Young Hua Ming LLP as auditor of the Company for the fiscal year ending December 31, 2023 and to authorize the directors of the Company to determine the remuneration of the auditor;To re-elect Wendy Hayes,

      12/19/23 9:35:05 PM ET
      $BNR
      Medical Specialities
      Health Care

    $BNR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cowen resumed coverage on Burning Rock Biotech

      Cowen resumed coverage of Burning Rock Biotech with a rating of Outperform

      10/15/21 7:18:12 AM ET
      $BNR
      Medical Specialities
      Health Care
    • CICC initiated coverage on Burning Rock Biotech with a new price target

      CICC initiated coverage of Burning Rock Biotech with a rating of Outperform and set a new price target of $39.94

      7/14/21 5:44:04 AM ET
      $BNR
      Medical Specialities
      Health Care

    $BNR
    SEC Filings

    See more
    • SEC Form 6-K filed by Burning Rock Biotech Limited

      6-K - Burning Rock Biotech Ltd (0001792267) (Filer)

      6/6/25 6:07:22 AM ET
      $BNR
      Medical Specialities
      Health Care
    • SEC Form 20-F filed by Burning Rock Biotech Limited

      20-F - Burning Rock Biotech Ltd (0001792267) (Filer)

      4/29/25 6:31:11 AM ET
      $BNR
      Medical Specialities
      Health Care
    • SEC Form 6-K filed by Burning Rock Biotech Limited

      6-K - Burning Rock Biotech Ltd (0001792267) (Filer)

      3/25/25 8:14:01 AM ET
      $BNR
      Medical Specialities
      Health Care

    $BNR
    Financials

    Live finance-specific insights

    See more
    • Burning Rock Reports First Quarter 2024 Financial Results

      GUANGZHOU, China, May 29, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"))), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2024. Recent Business Updates Early Detection THUNDER study for 6-cancer test was included in the Diagnosis and Treatment Guidelines for Primary Liver Cancer (2024 Edition) and the Expert Consensus on Detection and Clinical Application of Tumor DNA Methylation Markers (2024 Edition), showing an impressive performance of ELSA-seq using cfDNA in cancer detection an

      5/29/24 1:34:06 AM ET
      $BNR
      Medical Specialities
      Health Care
    • Burning Rock Schedules First Quarter of 2024 Earnings Release on May 29, 2024

      GUANGZHOU, China, May 23, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"))), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited financial results for the first quarter of 2024 before the U.S. market opens on May 29, 2024. Following the release, company management will host a conference call at 8:00 a.m. ET (8:00 p.m. Hong Kong time) on the same day to discuss its financial results for the first quarter of 2024. Please register in advance of the conference using the link provided below and dial in 15 minutes prio

      5/23/24 2:00:00 AM ET
      $BNR
      Medical Specialities
      Health Care
    • Burning Rock Reports Fourth Quarter and Full Year 2023 Financial Results

      GUANGZHOU, China, March 28, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"))), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months and the year ended December 31, 2023. 2023 Business Overview and Recent Updates Corporate Updates Completed profitability-driven organizational optimization, execution towards profitability well underway Early Detection   Following the Breakthrough Device Designation granted by the US Food and Drug Administration (FDA) for our OverC™ Multi-Cancer Detection

      3/28/24 5:16:22 PM ET
      $BNR
      Medical Specialities
      Health Care

    $BNR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Burning Rock Biotech Limited

      SC 13G/A - Burning Rock Biotech Ltd (0001792267) (Subject)

      11/14/24 12:29:09 PM ET
      $BNR
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Burning Rock Biotech Limited (Amendment)

      SC 13G/A - Burning Rock Biotech Ltd (0001792267) (Subject)

      2/14/24 4:05:59 PM ET
      $BNR
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Burning Rock Biotech Limited (Amendment)

      SC 13G/A - Burning Rock Biotech Ltd (0001792267) (Subject)

      2/14/24 12:45:51 PM ET
      $BNR
      Medical Specialities
      Health Care